Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study - Hart, A; Panaccione, R; Steinwurz, F (Gastroenterology, 2025)